![Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy | Oncology Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy | Oncology](https://www.frontiersin.org/files/Articles/52319/fonc-03-00155-HTML/image_m/fonc-03-00155-g001.jpg)
Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy | Oncology
![Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies](http://www.tropicalgastro.com/uploads/Untitnxjed-32.jpg)
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
![The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology](https://cdn.amegroups.cn/journals/pbpc/files/journals/1/articles/181/public/181-1292-1-PB.jpg)
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
![Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients](https://www.jcancer.org/v09/p0494/jcav09p0494g003.jpg)
Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients
![Persistent elevation of Ca 19-9 and an unexpected finding. A case report | Cirugía y Cirujanos (English Edition) Persistent elevation of Ca 19-9 and an unexpected finding. A case report | Cirugía y Cirujanos (English Edition)](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S2444050717300761:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w997EogCnBdOOD93cPFbanNdvmYPHt6bjyzOpfOlwJvwGBYc//ZwJBYMynuudQpd+r5uPgZn3Bk8bAnXmG/cZzggr8+Nhc/NIJ0RJJbkMNDWz98QaCsdYhUGqRFnAAM+isbIo1ebmdOETlhak8TUYhmbSXaCrOjF/5Gk4czEghiHsxjIwunYUS5qAabn/HLBYApGB3L2Kx9A6c27T0aVXwg7Sy47di7c+El1aVjNgygVGgQJWm7ZX82JA35r+3HjiV33cVfFGppsjlgKnqpk7V+s=)
Persistent elevation of Ca 19-9 and an unexpected finding. A case report | Cirugía y Cirujanos (English Edition)
![The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line](https://www.jcancer.org/v09/p4255/jcav09p4255g001.jpg)
The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line
![Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-020-65720-8/MediaObjects/41598_2020_65720_Fig2_HTML.png)
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
![Пакет изследвания за жената /CA 19-9, , СА 125 r.r PSA, и СЕА общ туморен маркер/, от Медикодиагностична лаборатория "Д-р Тошкина" Пакет изследвания за жената /CA 19-9, , СА 125 r.r PSA, и СЕА общ туморен маркер/, от Медикодиагностична лаборатория "Д-р Тошкина"](https://www.omed.bg/images/cache/product/4143_large.jpg)
Пакет изследвания за жената /CA 19-9, , СА 125 r.r PSA, и СЕА общ туморен маркер/, от Медикодиагностична лаборатория "Д-р Тошкина"
![Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-020-65720-8/MediaObjects/41598_2020_65720_Fig3_HTML.png)
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
![Evaluation of Four Tumor Markers (CEA, AFP, CA125 and CA19-9) on Sysmex HISCL- 5000 Immunoassay Analyzer | Insight Medical Publishing Evaluation of Four Tumor Markers (CEA, AFP, CA125 and CA19-9) on Sysmex HISCL- 5000 Immunoassay Analyzer | Insight Medical Publishing](https://www.aclr.com.es/articles-images/annals-clinical-four-tumor-marker-3-3-32-g001.png)
Evaluation of Four Tumor Markers (CEA, AFP, CA125 and CA19-9) on Sysmex HISCL- 5000 Immunoassay Analyzer | Insight Medical Publishing
![The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology](https://cdn.amegroups.cn/journals/pbpc/files/journals/1/articles/181/public/181-1293-1-PB.jpg)